Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma

Objective: To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Methods: We screened UHR patients with a survival of less than 24 months and we selected patients with a concurrent survival of more than 24 months as a control group. We retrospectively analyzed the clinical characteristics of UHR patients with newly diagnosed MM and screened related risk factors. Results: In total we analyzed 477 patients, which included 121 (25.4%) UHR patients and 356 (74.6%) control patients. Median overall survival (OS) and progression-free survival (PFS) of UHR patients was 10.5 months (7.5–13.5 months) and 6.3 months (5.4–7.2 months), respectively. Univariate logistic regression analysis showed that age > 65 years, hemoglobin (HGB) < 100 g/L, lactate dehydrogenase (LDH) > 250 U/L, serum creatinine (SCr) > 2 mg/dL, corrected serum calcium (CsCa) > 2.75 mmol/L, B-type natriuretic peptide (BNP) or N-terminal prohormone BNP (NT-proBNP) > 2 upper limit of normal (ULN), high-risk cytogenetics, Barthel index score, and International Staging System (ISS) stage III were associated with UHR MM. In a multivariate analysis, age > 65 years, LDH > 250 U/L, CsCa > 2.75 mmol/L, BNP or NT-proBNP > 2 ULN, high-risk cytogenetics, and Barthel index score were independent risk factors for UHR MM. Moreover, UHR patients had a worse response rate than control patients. Conclusion: Our study highlighted the characteristics of UHR MM patients and suggested that the combination of organ insufficiency and highly malignant myeloma cells resulted in poor outcomes of patients with UHR MM.

[1]  A. Gozzetti,et al.  Steps towards a Multiple Myeloma Cure? , 2022, Journal of personalized medicine.

[2]  Daniela Bassi-Dibai,et al.  Barthel Index is a valid and reliable tool to measure the functional independence of cancer patients in palliative care , 2022, BMC Palliative Care.

[3]  E. Kastritis,et al.  Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications , 2022, American journal of hematology/oncology.

[4]  S. Hadidi,et al.  High Dose (Conditioning) Regimens used prior to Autologous Stem Cell Transplantation in Multiple Myeloma. , 2022, Transplantation and cellular therapy.

[5]  Jiwang Zhang,et al.  High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions , 2022, Blood Cancer Journal.

[6]  D. Lad,et al.  Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World. , 2022, Clinical lymphoma, myeloma & leukemia.

[7]  D. Coffey,et al.  Diagnosis and Management of Multiple Myeloma: A Review. , 2022, JAMA.

[8]  I. Ghobrial,et al.  Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine , 2022, Nature Reviews Clinical Oncology.

[9]  Chaofeng Sun,et al.  Prognostic Potential of Heart Rate and Hypertension in Multiple Myeloma Patients , 2021, Frontiers in Cardiovascular Medicine.

[10]  I. Miyashiro,et al.  Barthel Index-based functional status as a prognostic factor in young and middle-aged adults with newly diagnosed gastric, colorectal and lung cancer: a multicentre retrospective cohort study , 2021, BMJ Open.

[11]  Shaji K. Kumar,et al.  Current approaches to management of high‐risk multiple myeloma , 2021, American journal of hematology.

[12]  Jingfen Jin,et al.  Activities of daily living measurement after ischemic stroke , 2021, Medicine.

[13]  L. Bao,et al.  Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients , 2020, Cancer medicine.

[14]  M. Dimopoulos,et al.  Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. , 2020, Clinical lymphoma, myeloma & leukemia.

[15]  M. Dimopoulos,et al.  A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial , 2019, Leukemia.

[16]  F. Sharifi,et al.  Iranian Version of Barthel Index: Validity and Reliability in Outpatients' Elderly , 2019, International journal of preventive medicine.

[17]  R. Sahoo,et al.  High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome , 2019, The Indian journal of medical research.

[18]  I. Samsonova,et al.  N-Terminal Fragment of Brain-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure , 2019, Bulletin of Experimental Biology and Medicine.

[19]  G. Abel,et al.  Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. , 2019, Journal of geriatric oncology.

[20]  F. Mahoney,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.

[21]  T. Wun,et al.  Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma , 2018, Journal of the National Cancer Institute.

[22]  H. Agis,et al.  N‐terminal B‐type natriuretic peptide (NT‐proBNP) is associated with disease severity in multiple myeloma , 2018, European journal of clinical investigation.

[23]  M. Dimopoulos,et al.  Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies , 2017, European journal of haematology.

[24]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Anderson,et al.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. , 2015, Blood.

[26]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[27]  T. Shen,et al.  Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. , 2014, Leukemia research.

[28]  H. Avet-Loiseau.  Ultra high-risk myeloma. , 2010, Hematology. American Society of Hematology. Education Program.

[29]  B. Barlogie,et al.  Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Barlogie,et al.  Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. , 2009, Blood.

[31]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[32]  Jason McCoy,et al.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[35]  D. Weber,et al.  Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. , 2019, Cancer treatment and research communications.